• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Louis DeGennaro named president, CEO of Leukemia & Lymphoma Society

Louis DeGennaro named president, CEO of Leukemia & Lymphoma Society

September 11, 2014
CenterWatch Staff

The Leukemia & Lymphoma Society (LLS) has appointed Louis J. DeGennaro, Ph.D., president and CEO, effective immediately.

DeGennaro has been interim president and CEO of LLS since February 2014 and leads the operations of this $300 million cancer patient advocacy agency with headquarters in White Plains, N.Y. He joined LLS in 2005 and was named chief mission officer in 2009, with responsibility for leadership of LLS's mission functions of research, patient access, education, public policy and advocacy.

DeGennaro has more than 25 years of research, drug development and executive management experience in academic and private sector settings. His previous academic appointments include research group leader, Max Planck Institute in Munich, Germany, where his laboratory was among the first to clone genes expressed exclusively in the nervous system; and associate professor of neurology and cell biology, University of Massachusetts Medical School.

Previous positions include senior director of molecular genetics at Wyeth Pharmaceuticals, where his department contributed to the development of pantoprazole (Protonix) to treat acid reflux disease, Effexor (Venlafaxine) for anxiety and depression and Mylotarg for leukemia; executive vice president for R&D at SynX Pharma, where he was responsible for the development of a point-of-care diagnostic test for congestive heart failure; and research manager at Streck, where he helped develop an FDA-cleared diagnostic test for AIDS/HIV.

DeGennaro was appointed by the U.S. Secretary of Health and Human Services in 2012 as a member of the National Center for Advancing Translational Sciences advisory council, and the Cures Acceleration Network review board at the NIH. He also is on the boards of BioTheryX, an early-stage biotechnology company and the Health Research Alliance, an alliance of non-profit funders of research.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing